Targets › HTR5A
2 programs from 1 company in 2 trials: 2 Phase 1; Other.
G protein-coupled receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone and a mitogen. Also functions as a receptor for ergot alkaloid derivatives and other psychoactive substances. (UniProt, P47898)
Open in Phaseline: the race on HTR5A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Hospital, Basel, Switzerland | DMT 5-HT receptor agonist, primarily 5-HT1A and 5-HT7 | HTR1A, HTR1B, HTR1D, HTR5A, HTR7 | Phase 1 | Healthy | – |
| University Hospital, Basel, Switzerland | LSD 5-HT receptor agonist, primarily 5-HT1A and 5-HT7 | HTR1A, HTR1B, HTR1D, HTR5A, HTR7 | Phase 1 | Healthy | – |
Healthy (2)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.